Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 149 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Donepezil hydrochloride (Aricept) Clear all
Terminated Phase 2 Interventional

Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease

NCT00704782
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
dimebon
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Phoenix, Arizona • Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Memory and Mental Health in Aging

NCT02988908
View directory record Official record
Conditions
Memory
Interventions
Donepezil, Placebos
Drug
Lead sponsor
Stanford University
Other
Eligibility
55 Years to 90 Years
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

NCT00570128
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil HCl, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Effects of Cholinergic Augmentation on Measures of Balance and Gait

NCT02206620
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Donepezil
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 2, 2026, 1:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

NCT00987220
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Placebo, donepezil (Aricept)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2011 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 4 Interventional

A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties

NCT00315367
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Donepezil HCI (drug)
Drug
Lead sponsor
Neurognostics
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2007 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Treatment of Residual Amblyopia With Donepezil

NCT01584076
View directory record Official record
Conditions
Amblyopia
Interventions
Donepezil, Patching
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Waltham, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 2, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders

NCT02487082
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Melatonin and Donepezil, Placebo
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
4 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Not applicable Interventional

Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease

NCT00467766
View directory record Official record
Conditions
Alzheimer Disease, Caregivers
Interventions
Psychosocial information, counseling, and support, Donepezil (Aricept)
Behavioral · Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 2 Interventional

VI-1121 for the Treatment Alzheimer's Disease

NCT01428362
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VI-1121, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
San Francisco, California • Santa Monica, California • Sunrise, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 2, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)

NCT05042102
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Donepezil + Cognitive remediation therapy (CRT), Donepezil + Placebo CRT, Placebo medication + Cognitive remediation therapy (CRT), Placebo medication + Placebo CRT
Combination Product
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 2, 2026, 1:16 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

NCT01345864
View directory record Official record
Conditions
Healthy
Interventions
Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI

NCT00483028
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
donezepil (Aricept)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Haven, Connecticut • Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2008 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Study of Donepezil in Fragile X Syndrome

NCT01120626
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
donepezil, sugar pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 29 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Use of Donepezil for Treatment of Cocaine Dependence

NCT00467389
View directory record Official record
Conditions
Cocaine Abuse and Dependence
Interventions
Donepezil, 5 mg daily, Oral Placebo
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

NCT00018278
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Aricept, Exelon, Nicoderm Patch
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2001
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 2, 2026, 1:16 PM EDT
Withdrawn Phase 3 Interventional

Improving Memory in Patients With Multiple Sclerosis

NCT00062972
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
donepezil, glucose
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 56 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 2, 2026, 1:16 PM EDT
Not listed Phase 3 Interventional

Enhancing Rehabilitation After Stroke

NCT00868010
View directory record Official record
Conditions
Ischemic Stroke
Interventions
donepezil, placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Warren, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 2, 2026, 1:16 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

NCT02696512
View directory record Official record
Conditions
Brain Injury
Interventions
Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care
Drug · Device · Dietary Supplement + 1 more
Lead sponsor
International Brain Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01527916
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
placebo, donepezil, ABT-126
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 2, 2026, 1:16 PM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

NCT01260922
View directory record Official record
Conditions
Healthy
Interventions
Donepezil Hydrochloride, Aricept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 2, 2026, 1:16 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

NCT02822573
View directory record Official record
Conditions
Cognitive Dysfunction, Memory Impairment
Interventions
Donepezil 5 mg, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
278
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 206 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 2, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

NCT06041789
View directory record Official record
Conditions
Osteoporosis
Interventions
Donepezil, Memantine
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 2, 2026, 1:16 PM EDT